

ForSight VISION5 (now Allergan) Information
Get Verified Emails For ForSight VISION5 (now Allergan)
Contact top employees from
ForSight VISION5 (now Allergan)
Summary
ForSight VISION5 is focused on developing non-invasive products that replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy. F...Show more
Organization Website | forsightvision5.com |
Social Links | |
Phone Number | (650)325-2050 |
Industries | |
Headquarters Location | 191 Jefferson Dr, Menlo Park, CA, 94025 US |
Employees Size | 10-50 employees |
Founded | 2010 |
Competitors
Founded | Type | Employees | Revenue | Funding | |
|---|---|---|---|---|---|
| 2004 | Privately Held | 500-1000 | - | $- | |
| - | - | 100-200 | - | $- |
Employees Turnover 4 quarter 2025
Length of Employment
Employee tenure at ForSight VISION5 (now Allergan) shows a diverse range of experience levels:
17% for 8–10 years83% have over 11 years of service at ForSight VISION5 (now Allergan)Discover More
Contact top employees from
ForSight VISION5 (now Allergan)
Similar Companies
FAQ
ForSight VISION5 (now Allergan) operates in the Pharma industries. More details can be found on the official website: forsightvision5.com.
The headquarters of ForSight VISION5 (now Allergan) are located in Menlo Park, United States.
You can contact ForSight VISION5 (now Allergan) by phone at (650)325-2050.
ForSight VISION5 (now Allergan) currently employs 10-50 people.
Well-known competitors of ForSight VISION5 (now Allergan) include Sygnature Discovery North America and LENZ Therapeutics.
Data Privacy
GDPR COMPLIANT
SignalHire complies with the General Data Protection Regulation (GDPR). SignalHire follows GDPR requirements, including but not limited to rights of data subjects to access, correct, or delete their personal information and supports the right to be forgotten.
CCPA COMPLIANT
SignalHire is CCPA-compliant and provides California residents the right to know, access, opt out, and request deletion of their personal data.






